(Q50543689)

English

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating

scientific article published on 6 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

thromboembolism

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Paul G. Richardson

1

object named as

Paul Richardson

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Kenneth C. Anderson

13

object named as

Kenneth Anderson

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

11

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Dixie-Lee Esseltine

14

object named as

Dixie-Lee Esseltine

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Helgi van de Velde

18

object named as

Helgi van de Velde

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Nuriet K Khuageva

3

object named as

Nuriet Khuageva

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

5

object named as

Ofer Shpilberg

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

María Victoria Mateos

12

object named as

Maria-Victoria Mateos

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

15

object named as

Andrew Cakana

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Maria Teresa Petrucci

8

object named as

Maria Teresa Petrucci

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

William Deraedt

17

object named as

William Deraedt

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

author name string

Rudolf Schlag

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Martin Kropff

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Marie-Christiane Vekemans

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Viktor Rossiev

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Jian Hou

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Kevin Liu

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Jesús F San Miguel

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

language of work or name

0 references

publication date

6 March 2011

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

British Journal of Haematology

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

153

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

212-221

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Lenalidomide in the treatment of multiple myeloma: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Effects of cancer-related anemia on clinical and quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Thromboembolic events with lenalidomide-based therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08569.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08569.X

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21375521

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50543689&oldid=2043645491"